痰热清联合布地奈德雾化吸入治疗慢性阻塞性肺疾病的疗效评价

Efficacy of Tanreqing Combined with Budesonide Aerosol Inhalation on Chronic Obstructive Pulmonary Disease

目的:探讨痰热清联合布地奈德雾化吸入治疗对慢性阻塞性肺疾病(COPD)的疗效的影响。方法:选取我院确诊为COPD患者80例,数字随机表法均分为对照组与观察组。对照组采取布地奈德吸入治疗,观察组在对照组基础上增加痰热清雾化治疗,连续治疗7d,观察两组治疗效果及安全性。结果:观察组治疗后有效率为90.00%高于对照组75.00%(P<0.05);观察组治疗后第1秒用力呼气容积占预计值百分比(FEV1%)、FEV1/FVC、呼气峰流速(PEF)、PaO2、SaO2及血清转化生长因子(TGF-β)均高于对照组(P<0.05),PaCO2、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)水平均低于对照组(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:两种药物联合治疗COPD疗效显著,可明显改善患者肺功能与气血指标且安全性好,可能与调节机体炎性因子水平有关。

Objective: To explorethe efficacy of Tanreqing combined with budesonideaerosol inhalation on chronic obstructive pulmonary disease(COPD). Methods: 80 COPD patients in our hospital were selected anddivided into control groupand observation group according to the random number table method. Control group was given budesonide inhalation while observation group wasgiven Tanreqing aerosol therapy on the basis of control group, and they were continuously treated for 7 d. The treatment effects and safety were observed in two groups. Results: The effective rate in observation group after treatment was higher than that in control group(90.00%vs 75.00%)(P<0.05). The FEV1%, FEV1/FVC, PEF, PaO2, SaO2 and TGF-βin observation group after treatment were higher than those in control group(P<0.05)while the PaCO2, IL-6 and IL-8 were lower than those in control group(P<0.05). There was no significant difference in incidence rate of adverse reactions between two groups(P>0.05). Conclusion: A combination of the two drugs has obviousefficacy on COPD, and it can clearly improve lung function and blood gas indexes, and it has good safety and may be related to regulation of inflammatory factors in body.